5134922
Last Update Posted: 2025-03-21
Recruiting status is unknown
Females accepted | 18 Years + |
Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
The primary purpose of this study is to provide continuing access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
Eligibility
Relevant conditions:
Breast Neoplasm Malignant Female
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Nadene Zack, MS
nzack@celcuity.com
844-310-3900
Data sourced from ClinicalTrials.gov